共 50 条
- [1] Neoadjuvant PD-1 blockade in NSCLCNature Reviews Clinical Oncology, 2018, 15 : 404 - 404David Killock
- [2] Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCJOURNAL OF THORACIC ONCOLOGY, 2020, 15 (05) : 816 - 826Gao, ShugengLi, NingGao, ShunyuXue, QiYing, JianmingWang, ShuhangTao, XiuliZhao, JunMao, YoushengWang, BingShao, KangLei, WendongWang, DaliLv, FangZhao, LiangZhang, FanZhao, ZiranSu, KaiTan, FengweiGao, YiboSun, NanWu, DaweiYu, YueLing, YunWang, ZhijieDuan, ChunjianTang, WeiZhang, LeiHe, ShunWu, NingWang, JieHe, Jie
- [3] Combining chemotherapy with PD-1 blockade in NSCLCPHARMACOLOGY & THERAPEUTICS, 2018, 186 : 130 - 137Mathew, MatthenEnzler, ThomasShu, Catherine A.Rizvi, Naiyer A.
- [4] Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLCJOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) : 503 - 509Rosner, SamuelForde, Patrick M.
- [5] Chemotherapy thorn PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLCJOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) : 499 - 502Hendriks, Lizza E. L.Remon, JordiReck, Martin
- [6] Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockadenpj Precision Oncology, 6Shuhang WangPei YuanBeibei MaoNing LiJianming YingXiuli TaoWei TangLei ZhangXiao GengFan ZhangQi XueLijia WuHenghui ZhangShugeng GaoJie He
- [7] Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Wang, ShuhangLi, NingMao, BeibeiYing, JianmingTao, XiuliTang, WeiZhang, LeiGeng, XiaoZhang, FanXue, QiWu, LijiaZhang, HenghuiGao, ShugengHe, Jie
- [8] Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockadeNPJ PRECISION ONCOLOGY, 2022, 6 (01)Wang, ShuhangYuan, PeiMao, BeibeiLi, NingYing, JianmingTao, XiuliTang, WeiZhang, LeiGeng, XiaoZhang, FanXue, QiWu, LijiaZhang, HenghuiGao, ShugengHe, Jie
- [9] Peripheral T Cell Repertoire Evolution in Resectable NSCLC Treated with Neoadjuvant PD-1 BlockadeJOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S293 - S294Zhang, J.Ji, Z.Caushi, J.El Asmar, M.Anagnostou, V.Cottrell, T.Chan, H. Y.Guo, H.Merghoub, T.Chaft, J.Wolchok, J.Reuss, J.Marrone, K.Naidoo, J.Gabrielson, E.Taube, J.Brahmer, J.Velculescu, V.Zhao, N.Hellmann, M.Forde, P.Pardoll, D.Yegnasubramanian, S.Ji, H.Smith, K.
- [10] Acquired resistance to PD-1 blockade in NSCLC.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Schoenfeld, Adam JacobRizvi, HiraMemon, DanishLuo, JiaPreeshagul, Isabel RuthSauter, Jennifer L.Plodkowski, Andrew J.Vanderbilt, ChadMiller, Martin L.Hellmann, Matthew David